Questcor Pharmaceuticals has a market cap of $1.47 billion and an enterprise value of $1.3 billion. This stock trades at a cheap valuation, with a trailing price-to-earnings of 9.74 and a forward price-to-earnings of 6.21. Its estimated growth rate for this year is 152%, and for next year it's pegged at 26.5%. This is a cash-rich company, since the total cash position on its balance sheet is $111.91 million and its total debt is zero.
The chief technology officer and vice president just
bought 55,000 shares, or about $1.31 million worth of stock, at $23.80 to $23.90 per share.
From a technical perspective, QCOR is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock plunged lower badly in late September, with shares dropping from $52 to its recent low of $17.12 a share. Following that plunge, shares of QCOR have started to uptrend sharply from $17.12 to its recent high of $26.20 a share. During that uptrend, shares of QCOR have been mostly making higher lows and higher highs, which is bullish technical price action. That move has now pushed QCOR within range of triggering a near-term breakout trade.
If you're in the bull camp on QCOR, then I would look for long-biased once this stock manages to break out above some near-term overhead resistance levels at $25.95 to $26.20 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 5,510,080 shares. If that breakout triggers soon, then QCOR will set up to re-test or possibly take out its next major overhead resistance levels at $30.89 to $32.50 a share. Any high-volume move above those levels will then put $38.26 into focus for QCOR.
One biotechnology and drugs player that insiders are warming up to here is
(IRWD - Get Report)
. This company discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. Insiders are buying this stock into some modest weakness, since shares are down by just over 10% in the last six months.
Ironwood Pharmaceuticals has a market cap of $1.24 billion and an enterprise value of $1.02 billion. Its estimated growth rate for this year is -27.7%, and for next year it's pegged at 155.4%. This is a cash-rich company, since the total cash position on its balance sheet is $193.32 million and its total debt is just $641,000.